AstraZeneca says 87.5% of Lynparza-treated patients alive at six years in trial

Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, AstraZeneca announed. These results were presented at the San Antonio Breast Cancer Symposium 2024 and “build on the positive primary results published in The New England Journal of Medicine,” the company added. At a median follow-up of 6.1 years in eligible patients, who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, results showed Lynparza reduced the risk of death by 28% versus placebo. In addition, 87.5% of patients treated with LYNPARZA remained alive versus 83.2% of those on placebo.